Reconsidering Adjuvant Immunotherapy for Tuberculosis
The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Shortened regimens for treatment of pulmonary tuberculosis (TB) are urgently needed to facilitate its global eradication. Prolonged treatment is presently required to prevent relapse, which is thought to arise from persisting foci of semidormant infection contained within granulomas. METHODS: The medical literature was reviewed to identify clinical trials of adjuvant TB immunotherapy, as well as other studies of the relationship between immune status and TB relapse or reactivation. RESULTS: Four studies of therapeutic interferon indicated its inability to effectively augment the mycobactericidal capacity of lung macrophages. One randomized, placebo-controlled trial of therapeutic interleukin-2 found that it delayed the microbiologic response to treatment, whereas 2 controlled trials of anti-tumor necrosis factor (TNF) therapies (high-dose prednisolone and etanercept [a soluble TNF receptor]) found that these interventions significantly accelerated the response to treatment. Four retrospective studies were identified in which the response to TB therapy was accelerated and/or the relapse risk was reduced in persons with human immunodeficiency virus coinfection; one study reported that immune reconstitution syndrome due to use of antiretroviral therapy was associated with increased risk of relapse. Several studies indicated that granulomas may be efficiently targeted and disrupted by the anti-TNF antibody infliximab, apparently because of its ability to bind to cell-surface TNF and to induce apoptosis in TNF-expressing cells. CONCLUSIONS: These findings support the hypothesis that the granulomatous host response to TB may paradoxically protect sequestered mycobacteria from administered anti-TB therapy and that treatment may be improved by therapeutic disruption of granulomas. Clinical trials to test this hypothesis are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells
Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., et al. (1997) · Nature · doi:10.1038/385729a0 · Cited by 3,149 · cited 1×
“ing domains, as a soluble homotrimer [26, 27].”
Flynn, J. L., Goldstein, M. M., Chan, J., Triebold, K. J., Pfeffer, K., Lowenstein, C. J., Schrelber, R., Mak, T. W., & Bloom, B. R. (1995) · Immunity · doi:10.1016/1074-7613(95)90001-2 · Cited by 1,677 · cited 1×
“As a result, animals deficient in TNF are highly susceptible to granulomatous infections [41].”
BackgroundMcKinney, J. D., zu Bentrup, K. H., Muñoz-Elías, E. J., Miczak, A., Chen, B., Chan, W.-T., Swenson, D., Sacchettini, J. C., Jacobs, W. R., & Russell, D. G. (2000) · Nature · doi:10.1038/35021074 · Cited by 1,360 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundKindler, V., Sappino, A.-P., Grau, G. E., Piguet, P.-F., & Vassalli, P. (1989) · Cell · doi:10.1016/0092-8674(89)90676-4 · Cited by 1,254 · cited 1×
“tuberculosis infection and inhibits the orderly formation of granulomas [37, 38].”
BackgroundChan, J., Xing, Y., Magliozzo, R. S., & Bloom, B. R. (1992) · The Journal of experimental medicine · doi:10.1084/jem.175.4.1111 · Cited by 1,062 · cited 1×
“production of reactive nitrogen intermediates, such as nitric oxide [16, 17].”
BackgroundGranulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists
Wallis, R. S., Broder, M. S., Wong, J. Y., Hanson, M. E., & Beenhouwer, D. O. (2004) · Clinical Infectious Diseases · doi:10.1086/383317 · Cited by 977
Self-citationInhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., & Schoolnik, G. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030205 · Cited by 966 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundEtanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910 · cited 1×
“Crohn disease, sarcoidosis, or Wegener granulomatosis [68-71].”
Interferon-γ –Receptor Deficiency in an Infant with Fatal Bacille Calmette–Guérin Infection
Jouanguy, E., Altare, F., Lamhamedi, S., Revy, P., Emile, J.-F., Newport, M., Levin, M., Blanche, S., Seboun, E., Fischer, A., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352604 · Cited by 895
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 836 · cited 1×
“among patients who are treated with prednisone or etanercept [51, 52], indicating that these treatments interfere with granuloma formation and/or maintenance in humans, as they do in experimental animals.”
BackgroundRoach, D. R., Bean, A. G. D., Demangel, C., France, M. P., Briscoe, H., & Britton, W. J. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4620 · Cited by 782 · cited 1×
“In addition, TNF blockade also reduces the microbicidal activity of macrophages and NK cells [39, 40].”
BackgroundRegulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin
Sherman, D. R., Voskuil, M., Schnappinger, D., Liao, R., Harrell, M. I., & Schoolnik, G. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121172498 · Cited by 729 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundVan den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723 · cited 1×
“face TNF [73-76].”
Park, H., Guinn, K. M., Harrell, M. I., Liao, R., Voskuil, M. I., Tompa, M., Schoolnik, G. K., & Sherman, D. R. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03474.x · Cited by 712 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundReported tuberculosis in the United States 2013
Aids, V. H., & Prevetion, T. (2014) · Medical Entomology and Zoology · Cited by 608
Paradoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS
NARITA, M., ASHKIN, D., HOLLENDER, E. S., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9712001 · Cited by 608 · cited 1×
“[62] found a 6-fold increased risk of subsequent tuberculosis relapse in patients who experienced IRIS during early tuberculosis treatment.”
BackgroundBaert, F. J., D'Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 462 · cited 1×
“can induce long-lasting remissions and closure of chronic enteric fistulas [72].”
BackgroundVoskuil, M. I., Visconti, K. C., & Schoolnik, G. K. (2004) · Tuberculosis · doi:10.1016/j.tube.2004.02.003 · Cited by 448
Lee, J., Slifman, N. R., Gershon, S. K., Edwards, E. T., Schwieterman, W. D., Siegel, J. N., Wise, R. P., Brown, S. L., Udall, J. N., & Braun, M. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10583 · Cited by 443
Sonnenberg, P., Murray, J., Glynn, J. R., Shearer, S., Kambashi, B., & Godfrey-Faussett, P. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06712-5 · Cited by 433 · cited 1×
“Only 1 prospective study of the influence of HIV infection on tuberculosis relapse in the absence of antiretroviral therapy has been reported [58].”
Background(2002) · The Lancet · doi:10.1016/s0140-6736(02)09742-8 · Cited by 409 · cited 1×
“In humans, cavitary disease is associated with delayed sputum culture conversion and increased risk of subsequent relapse [14].”
BackgroundEtanercept for the Treatment of Stage II and III Progressive Pulmonary Sarcoidosis
Utz, J. P., Limper, A. H., Kalra, S., Specks, U., Scott, J. P., Vuk-Pavlovic, Z., & Schroeder, D. R. (2003) · Chest · doi:10.1378/chest.124.1.177 · Cited by 390 · cited 1×
“Crohn disease, sarcoidosis, or Wegener granulomatosis [68-71].”
Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis
Manganelli, R., Dubnau, E., Tyagi, S., Kramer, F. R., & Smith, I. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01212.x · Cited by 370
Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol
Condos, R., Rom, W. N., & Schluger, N. W. (1997) · The Lancet · doi:10.1016/s0140-6736(96)12273-x · Cited by 316 · cited 1×
“[18].”
Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis.
Barnes, P. F., Fong, S. J., Brennan, P. J., Twomey, P. E., Mazumder, A., & Modlin, R. L. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.1.149 · Cited by 310
Flesch, I., & Kaufmann, S. H. E. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.12.4408 · Cited by 300 · cited 1×
“production of reactive nitrogen intermediates, such as nitric oxide [16, 17].”
BackgroundBarnes, P. F., Chatterjee, D., Abrams, J. S., Lu, S., Wang, E., Yamamura, M., Brennan, P. J., & Modlin, R. L. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.2.541 · Cited by 294 · cited 1×
“Monocytes express TNF after phagocytosis of mycobacteria or after stimulation by tnycobacterial proteins or glycolipids [26, 28-30].”
BackgroundIncreased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists
Bergstrom, L., Yocum, D. E., Ampel, N. M., Villanueva, I., Lisse, J., Gluck, O., Tesser, J., Posever, J., Miller, M., Araujo, J., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20454 · Cited by 268
Hirsch, C. S., Ellner, J. J., Russell, D. G., & Rich, E. A. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.152.2.743 · Cited by 258 · cited 1×
“In addition, TNF blockade also reduces the microbicidal activity of macrophages and NK cells [39, 40].”
BackgroundEffectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis
Lamprecht, P. (2002) · Rheumatology · doi:10.1093/rheumatology/41.11.1303 · Cited by 245
Deitch, R. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90534-8 · Cited by 245
Karakousis, P. C., Yoshimatsu, T., Lamichhane, G., Woolwine, S. C., Nuermberger, E. L., Grosset, J., & Bishai, W. R. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040646 · Cited by 237 · cited 1×
“[ 10] recently reported”
Wallis, R. S., Kyambadde, P., Johnson, J. L., Horter, L., Kittle, R., Pohle, M., Ducar, C., Millard, M., Mayanja-Kizza, H., Whalen, C., et al. (2004) · AIDS · doi:10.1097/00002030-200401230-00015 · Cited by 226
Self-citationAdalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept
Shen, C., Assche, G. V., Colpaert, S., Maerten, P., Geboes, K., Rutgeerts, P., & Ceuppens, J. L. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02309.x · Cited by 223 · cited 1×
“face TNF [73-76].”
Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction
Wallis, R. S., Broder, M., Wong, J., & Beenhouwer, D. (2004) · Clinical Infectious Diseases · doi:10.1086/424455 · Cited by 219 · cited 2×
“The risk posed by infliximab subsequently decreases (consistent with reactivation of preexisting latent infection), whereas that of etanercept does not (consistent with the inability to contain incident tuberculosis infection) [52].”
BackgroundSelf-citationAssessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 Months
Mitchison, D. A. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.4.1062 · Cited by 215
Pulmonary Hypertension and Right Heart Failure in Chronic Obstructive Pulmonary Disease
Naeije, R. (2005) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200407-037ms · Cited by 202
Di Sabatino, A. (2004) · Gut · doi:10.1136/gut.53.1.70 · Cited by 186 · cited 1×
“face TNF [73-76].”
Garcia Vidal, C., Rodriguez Fernandez, S., Martinez Lacasa, J., Salavert, M., Vidal, R., Rodriguez Carballeira, M., & Garau, J. (2005) · Clinical Infectious Diseases · doi:10.1086/427941 · Cited by 180 · cited 1×
“IRIS has been reported in infliximab-associated tuberculosis cases after withdrawal of infliximab [77].”
BackgroundMechanisms of iron regulation in mycobacteria: role in physiology and virulence
Rodriguez, G. M., & Smith, I. (2003) · Molecular Microbiology · doi:10.1046/j.1365-2958.2003.03384.x · Cited by 162 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundWallis, R. S., Amir-Tahmasseb, M., & Ellner, J. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.9.3348 · Cited by 158 · cited 1×
“ing domains, as a soluble homotrimer [26, 27].”
Self-citationMycobacterium tuberculosis Genes Induced during Infection of Human Macrophages
Dubnau, E., Fontán, P., Manganelli, R., Soares-Appel, S., & Smith, I. (2002) · Infection and Immunity · doi:10.1128/iai.70.6.2787-2795.2002 · Cited by 150 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundAlgood, H. M. S., Lin, P. L., Yankura, D. J., Jones, A. C., Chan, J., & Flynn, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.11.6846 · Cited by 145 · cited 1×
“tuberculosis infection and inhibits the orderly formation of granulomas [37, 38].”
BackgroundValone, S. E., Rich, E. A., Wallis, R. S., & Ellner, J. J. (1988) · Infection and Immunity · doi:10.1128/iai.56.12.3313-3315.1988 · Cited by 142
Self-citationMayanja‐Kizza, H., Jones‐Lopez, E., Okwera, A., Wallis, R. S., Ellner, J. J., Mugerwa, R. D., Whalen, C. C., & Uganda–Case Western Research Collaboration (2005) · The Journal of Infectious Diseases · doi:10.1086/427995 · Cited by 136
Self-citationSustained Increases In Cd4 Cell Counts In Asymptomatic Human
Andrieu, J., Lu, W., & Levy, R. (1995) · The Journal of Infectious Diseases · doi:10.1093/infdis/171.3.523 · Cited by 129
Bekker, L., Maartens, G., Steyn, L. M., & Kaplan, G. (1998) · The Journal of Infectious Diseases · doi:10.1086/517479 · Cited by 129 · cited 1×
“TNF levels increase shortly after initiation of antituberculosis therapy [33], possibly because of a release of microbial constituents that stimulate TNF production [34–36].”
BackgroundEl‐Sadr, W. M., Perlman, D. C., Matts, J. P., Nelson, E. T., Cohn, D. L., Salomon, N., Olibrice, M., Medard, F., Chirgwin, K. D., Mildvan, D., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/520275 · Cited by 118 · cited 1×
“of the study and that the main end point (relapse) could not be assessed because rates were unexpectedly low in all treatment arms [61].”
BackgroundRandomized Trial of Adjunctive Interleukin-2 in Adults with Pulmonary Tuberculosis
Johnson, J. L., Ssekasanvu, E., Okwera, A., Mayanja‐Kizza, H., Hirsch, C. S., Nakibali, J. G., Jankus, D. D., Eisenach, K. D., Boom, W. H., Ellner, J. J., et al. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1359oc · Cited by 115 · cited 1×
“HIV-uninfected patients with drug-susceptible tuberculosis [25].”
Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study
Suárez-Méndez, R., García‐García, I., Olivera, N. F., Valdés-Quintana, M., Milanés-Virelles, M. T., Carbonell, D., Molina, D. M., Valenzuela‐Silva, C., & López-Saura, P. A. (2004) · BMC Infectious Diseases · doi:10.1186/1471-2334-4-44 · Cited by 104
Ribeiro‐Rodrigues, R., Có, T. R., Johnson, J. L., Ribeiro, F. C., Palaci, M., Sá, R. T., Maciel, E. L. N., Lima, F. E. P., Dettoni, V. D. V., Toossi, Z., et al. (2002) · Clinical and Vaccine Immunology · doi:10.1128/cdli.9.4.818-823.2002 · Cited by 94 · cited 1×
“Levels subsequently decrease as the bacillary burden is reduced by treatment [31].”
BackgroundJohnson, B. J. B., Bekker, L., Rickman, R., Brown, S. T., Lesser, M. D., Ress, S., Willcox, P. A., Steyn, L. M., & Kaplan, G. (1997) · Tubercle and Lung Disease · doi:10.1016/s0962-8479(97)90026-5 · Cited by 87 · cited 1×
“patients with MDR tuberculosis found that the daily regimen appeared to decrease sputum acid-fast bacilli counts [24].”
BackgroundKoh, W., Kwon, O. J., Suh, G. Y., Chung, M. P., Kim, H., Lee, N. Y., Kim, T., & Lee, K. S. (2004) · Journal of Korean Medical Science · doi:10.3346/jkms.2004.19.2.167 · Cited by 79 · cited 1×
“[21] 6 2 MU of IFN-g 3 times per week by aerosol for 6 months No microbiologic effect”
MethodAerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis.
Giosuè, S., Casarini, M., Ameglio, F., ZANGRILLI, P., Palla, M., Altieri, A. M., & Bisetti, A. (2000) · PubMed · Cited by 74
Brindle, R. J., Odhiambo, J. A., & Mitchison, D. A. (2001) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-1-2 · Cited by 73 · cited 1×
“trials using other sputum surrogate markers concur with this observation [13, 60].”
ResultAung, H. L., Toossi, Z., Wisnieski, J. J., Wallis, R. S., Culp, L. A., Phillips, N. B., Phillips, M., Averill, L. E., Daniel, T. M., & Ellner, J. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118910 · Cited by 62
Self-citationTuberculosis Research Centre (1983) · Tubercle · doi:10.1016/0041-3879(83)90032-6 · Cited by 62
Prednisolone in Treatment of Pulmonary Tuberculosis: A Controlled Trial
Horne, N. W. (1960) · BMJ · doi:10.1136/bmj.2.5215.1751 · Cited by 57
Randhawa, P. S. (1990) · Pathology · doi:10.3109/00313029009063555 · Cited by 51 · cited 1×
“The mouse may be a poor model in which to study the therapeutic effects of granuloma disruption, however, because murine tuberculosis granulomas are loose collections of activated and epithelioid macrophages and lymphocytes that lack the multinucleated giant cells, necrosis, caseation, and cavitation characteristic of…”
BackgroundWallis, R. S., Kalayjian, R. C., Jacobson, J. M., Fox, L. M., Purdue, L., Shikuma, C. M., Arakaki, R. F., Snyder, S. W., Coombs, R. W., Bosch, R. J., et al. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200303010-00006 · Cited by 48
Self-citationBilaçeroğlu, S., Perim, K., Büyükşirin, M., & Çelikten, E. (1999) · PubMed · Cited by 47
Wallis, R. S., Paranjape, R., & Phillips, M. (1993) · Infection and Immunity · doi:10.1128/iai.61.2.627-632.1993 · Cited by 45 · cited 1×
“Monocytes express TNF after phagocytosis of mycobacteria or after stimulation by tnycobacterial proteins or glycolipids [26, 28-30].”
BackgroundSelf-citationRaju, B., Hoshino, Y., Kuwabara, K., Belitskaya, I., Prabhakar, S., Canova, A., Gold, J. A., Condos, R., Pine, R. I., Brown, S. M., et al. (2004) · Infection and Immunity · doi:10.1128/iai.72.3.1275-1283.2004 · Cited by 44 · cited 1×
“lated in the lung in patients with tuberculosis and that therapeutic aerosol IFN-y has relatively little additional effect [23].”
BackgroundFlynn, J. L., Cooper, A. M., & Bishai, W. R. (2004) · Wiley eBooks · doi:10.1128/9781555817657.ch36 · Cited by 42
Mycobacterium tuberculosis gene expression in macrophages
Dubnau, E., & Smith, I. (2003) · Microbes and Infection · doi:10.1016/s1286-4579(03)00090-x · Cited by 39 · cited 1×
“oxygen deprivation or intracellular growth in macrophages [ 1-9].”
BackgroundTreating Crohn's Disease by Inducing T Lymphocyte Apoptosis
van den Brande, J. M. H., Peppelenbosch, M. P., & van Deventer, S. J. H. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04628.x · Cited by 37 · cited 1×
“face TNF [73-76].”
Infliximab Treatment of Sarcoidosis
Serio, R. N. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c249 · Cited by 36 · cited 1×
“Crohn disease, sarcoidosis, or Wegener granulomatosis [68-71].”
Joloba, M. L., Johnson, J. L., Namale, A., Morrissey, A. B., Assegghai, A. E., Mugerwa, R. D., Ellner, J. J., & Eisenach, K. D. (2000) · PubMed · Cited by 28
Wallis, R. S., Phillips, M., Johnson, J. L., Teixeira, L., Rocha, L. M. C., Maciel, E. L. N., Rose, L. M., Wells, C. D., Palaci, M., Dietze, R., et al. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1302-1304.2001 · Cited by 28
Self-citationSong, X.-Y., Fox, F. E., Gallo, M. A., Rosenberg, A. S., Jordan, R. E., Shealy, D. J., & Wagner, C. L. (2002) · The Journal of Infectious Diseases · doi:10.1086/338451 · Cited by 17 · cited 1×
“Some TNF blockers (including infliximab) are highly specific for human TNF [57].”
BackgroundBatten, J. C., & McCune, R. M. (1957) · PubMed · Cited by 13
Pentoxifylline in Human Immunodeficiency Virus– Positive Tuberculosis: Safety at 4 Years
Wallis, R. S., Johnson, J. L., Okwera, A., Nsubuga, P., Whalen, C. C., Mugerwa, R. D., & Ellner, J. J. (1998) · The Journal of Infectious Diseases · doi:10.1086/314528 · Cited by 13
Self-citationDhillon, J., & Da, M. (1989) · PubMed · Cited by 12
Oliveira, M. M., da Silva, J. C. S., Costa, J. F., Amim, L. H. L. V., Loredo, C., Melo, H. L., Queiroz, L. F., Mello, F. C. D. Q., Silva, J. R. L. E., Kritski, A. L., et al. (2004) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132004000400012 · Cited by 11
Research works printed but not linked: 10
- O’Brien RJ, 2001, Global Alliance for TB Drug Development. Tuberculosis, 81, 1
- Giosue S, 2000, Eur Cytokine Netw, 11, 99
- InterMune investor relations press release: InterMune enrolls first patient in phase III trial in multidrug-resistant tuberculosis. 2000. Available at: http://www.hopkins-tb.org/news/7-31-2000.shtml. Accessed 18 May 2005.
- de Oliveira MM, 2004, Jornal Brasileiro Pneumologia, 30, 461
- East African-British Medical Research Councils, 1974, Lancet, 2, 237
- Bilaceroglu S, 1999, Int J Tuberc Lung Dis, 3, 47
- Dhillon J, 1989, Br J Exp Pathol, 70, 103
- Batten JC, 1957, Br J Exp Pathol, 38, 424
- Flynn JL, 2004, Tuberculosis. Philadelphia: Lippincott Williams & Wilkins, 237
- Joloba ML, 2000, Int J Tuberc Lung Dis, 4, 528
Cited by
Roca, F. J., & Ramakrishnan, L. (2013) · Cell · doi:10.1016/j.cell.2013.03.022 · Cited by 592
“Second, that these susceptibility pathways could be TNF-mediated is supported by a clinical trial from Uganda showing that pulmonary TB patients had increased clearance of sputum bacteria when treated with TNF blocking agents (Wallis, 2005).”
ResultHost Genotype-Specific Therapies Can Optimize the Inflammatory Response to Mycobacterial Infections
Tobin, D. M., Roca, F. J., Oh, S. F., McFarland, R., Vickery, T. W., Ray, J. P., Ko, D. C., Zou, Y., Bang, N. D., Chau, T. T. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.023 · Cited by 580
“In addition, anti-TNF therapies have been reported to accelerate the bacteriological response in pulmonary TB patients (Wallis, 2005).”
BackgroundCurrent diagnosis and management of peripheral tuberculous lymphadenitis.
Fontanilla, J.-M., Barnes, A., & von Reyn, C. F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir454 · Cited by 299
“Adjuvant immunotherapy with anti–tumor necrosis factor agents has been studied in small numbers of patients for routine treatment of all forms of tuberculosis, but available data are insufficient to make a recommendation [51].”
BackgroundTumour necrosis factor antagonists: structure, function, and tuberculosis risks
Wallis, R. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70227-5 · Cited by 275
Self-citationThe risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
Bumbacea, D., Arend, S. M., Eyuboglu, F., Fishman, J. A., Goletti, D., Ison, M. G., Jones, C. E., Kampmann, B., Kotton, C. N., Lange, C., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00000712 · Cited by 264
“Potential improvement could be obtained by new drug combinations including novel drugs such as the diarylquinoline TMC207 [167], or combinations with immunopotentiators [168, 169].”
Background
Metadata
- Authors
- Wallis, R. S.
- Affiliations
- Pharmaceutical Product Development (United States) (US)
- Corresponding author
- Wallis, Robert S.
- ORCID
- Wallis, Robert S.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-15
- Volume
- 41
- Issue
- 2
- Pages
- 201-208
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2133199321
- Cited by
- 121
- References
- 75
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 7 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 13
- FWCI
- 1.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Louisiana State University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- pulmonary tuberculosis, adjuvant immunotherapy, tuberculosis relapse, granuloma, anti-TNF therapy, infliximab, etanercept, prednisolone, interleukin-2, interferon therapy, HIV coinfection, immune reconstitution inflammatory syndrome, antiretroviral therapy, tuberculosis treatment response
- MeSH terms
- Antitubercular Agents, Humans, Immunotherapy, Tuberculosis, Pulmonary, Drug Resistance, Multiple, Bacterial
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.